Lorigerlimab - CAS 2416595-46-3

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that inhibits PD-1 and CTLA-4 to enhance T-cell responses, currently being investigated for metastatic castration-resistant prostate cancer (mCRPC) [1] [2] [3].

PD-1/PD-L1

Immunology/Inflammation, Cell Cycle/Checkpoint, Apoptosis

2416546

-20°C

Ice Packs

Inhibitory Antibodies